Suva Plans Its First CLO Purchases, Targeting 2% of a CHF 59 Billion Portfolio

Suva, the Swiss not-for-profit accident insurer, is preparing to buy collateralised loan obligations for the first time. Its chief investment officer, Christoph Bianchet, has set a target of 2% of the portfolio, which works out to about CHF 1.2 billion, and for now the buying will be limited to triple-A rated European CLO tranches. Suva has said it is not moving into triple-B, double-B or single-B tranches, or into CLO equity, at this stage.

Who Suva is and how it invests

Suva is a large Swiss insurer with total assets of CHF 59 billion in 2025, up from CHF 57.9 billion in 2024, a rise of about 1.9%. Bianchet has been at Suva for 13 years. Almost all of the portfolio is run actively: 99% is managed actively, and Suva reports that it has underperformed its strategic benchmark in only 3 of the last 21 years, which is 14% of the period by count. It returned 5.5% in 2024 and 4.3% in 2025, against a 10-year average of 3.4%. The 2025 figure was therefore a step down from 2024 but still about 0.9 percentage points above the decade average.

That record matters for how GPs read the move. An investor that has kept pace with or beaten its benchmark in 18 of 21 years is making a deliberate choice here, and the narrow scope of the first step, senior tranches only, suggests a disciplined entry rather than a broad credit program.

Why triple-A, and why now

The timing is tied to regulation. A change to the EU insurance capital regime, Solvency II, takes effect in January 2027 and lowers the capital charge on high-quality CLO tranches. Suva reports under the Swiss Solvency Test rather than Solvency II directly, so the change does not apply to it directly, but it points to where European insurers will be buying and to a deeper, better priced market for senior tranches. Bianchet has also drawn a clear line between today's structures and the CLOs that existed before 2007, which he describes as a very different product.

A 2% target is small next to the whole book, and it should be read that way. The CHF 1.2 billion figure is about 2.03% of CHF 59 billion, and it is a target for the allocation rather than a commitment already made. We have not seen a stated timetable for building it.

What else is on Suva's list

CLOs are one part of a wider rebalancing. Suva is also closing gaps in its direct real estate allocation, with residential property and mortgage lending named as the routes. In private equity it is keeping existing positions without accelerating, and it continues a modest, ongoing allocation to secondary transactions. That mix, a new senior credit sleeve, more real assets and a steady but unexpanded private equity book, is the pattern of an insurer weighing capital charges as closely as headline returns. It echoes what we saw in our look at how US foundations are splitting their alternatives allocations, where fixed income and private markets moved in different directions at different types of LP. A sovereign investor weighing a fixed income mandate showed the same appetite for rated credit in the reported Gulf bond mandate under review at Saudi Arabia's PIF.

What GPs should do now

For managers of European CLOs, Suva is a new buyer of senior paper, and the practical step is to be on the list of managers whose triple-A tranches clear its criteria. Because Suva is an active investor with a long record, the approach should be direct and technical: portfolio quality data, manager track record through the cycle and tranche structure matter more than a fundraising narrative.

For private equity managers raising a Fund II or III, the message is plainer. Suva is maintaining its private equity positions, not adding to them, so a fund commitment in the near term is unlikely. The opening is for secondaries and for residential real estate or mortgage lending strategies that fit the gap Suva has identified. A credible approach names the exact sleeve, shows a European residential or mortgage track record, and relies on a warm introduction through a shared investor rather than a cold email, since an investor that runs its book actively will give a warm path more weight.

Managers from outside Switzerland should also remember how LPs in the region think about capital. A buyer that reports under Swiss rules and looks at EU capital changes cares about rating, liquidity and look-through. Lead with those and leave the return projections to the second page. Keep a note of other European LPs that are reacting to the same capital change, since the same logic will reach other insurers.

What to watch next

Watch for the first CLO tranches Suva buys, the managers it chooses, and whether the 2% target is revised once the January 2027 capital change is in force. FundLinx members can see which insurers are building credit allocations this quarter.

FundLinx Intelligence | FundLinx.ai